Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 8815818 Phagocytic cell delivery of RNAI

Patent 8815818 was granted and assigned to Rxi Pharmaceuticals Corporation on August, 2014 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
‌
Rxi Pharmaceuticals Corporation
Date Filed
July 17, 2009
Date of Patent
August 26, 2014
Patent Application Number
13054696
Patent Citations Received
‌
US Patent 12104172 Processes for generating TIL products enriched for tumor antigen-specific t-cells
0
‌
US Patent 11767527 Modified oligonucleotides targeting SNPs
‌
US Patent 11926828 Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
0
‌
US Patent 12024706 Modified oligonucleotides targeting SNPs
0
‌
US Patent 12077755 Bioactive conjugates for oligonucleotide delivery
0
‌
US Patent 11667915 RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
0
‌
US Patent 11702659 Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
0
‌
US Patent 11713446 Processes for generating TIL products enriched for tumor antigen-specific T-cells
0
‌
US Patent 11753638 Conjugated oligonucleotides
Patent Inventor Names
Dmitry Samarsky
0
Tod M. Woolf
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8815818
Patent Primary Examiner
‌
Brian Whiteman

Find more entities like US Patent 8815818 Phagocytic cell delivery of RNAI

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.